Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 76,300 shares, a decrease of 10.1% from the October 15th total of 84,900 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is presently 4.7 days.

Genmab A/S Price Performance

GNMSF traded down $7.79 on Monday, reaching $212.71. 1,000 shares of the company traded hands, compared to its average volume of 2,488. The stock’s 50 day moving average price is $236.51 and its 200-day moving average price is $258.78. The company has a market cap of $13.90 billion, a price-to-earnings ratio of 20.45 and a beta of 1.07. Genmab A/S has a 52-week low of $202.30 and a 52-week high of $334.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.